PT1017413E - Formulacoes liquidas de interferao (beta) - Google Patents

Formulacoes liquidas de interferao (beta)

Info

Publication number
PT1017413E
PT1017413E PT98950074T PT98950074T PT1017413E PT 1017413 E PT1017413 E PT 1017413E PT 98950074 T PT98950074 T PT 98950074T PT 98950074 T PT98950074 T PT 98950074T PT 1017413 E PT1017413 E PT 1017413E
Authority
PT
Portugal
Prior art keywords
beta
buffered
formulations
hsa
contain
Prior art date
Application number
PT98950074T
Other languages
English (en)
Inventor
Thomas Siklosi
Hans Hofer
Michael Tschope
Peter Schroeder
Original Assignee
Rentschler Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1017413(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rentschler Biotech Gmbh filed Critical Rentschler Biotech Gmbh
Publication of PT1017413E publication Critical patent/PT1017413E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Gyroscopes (AREA)
PT98950074T 1997-09-23 1998-09-23 Formulacoes liquidas de interferao (beta) PT1017413E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97116562 1997-09-23

Publications (1)

Publication Number Publication Date
PT1017413E true PT1017413E (pt) 2003-02-28

Family

ID=8227392

Family Applications (2)

Application Number Title Priority Date Filing Date
PT02004883T PT1224940E (pt) 1997-09-23 1998-09-23 Formulacoes liquidas de intrferao beta
PT98950074T PT1017413E (pt) 1997-09-23 1998-09-23 Formulacoes liquidas de interferao (beta)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT02004883T PT1224940E (pt) 1997-09-23 1998-09-23 Formulacoes liquidas de intrferao beta

Country Status (13)

Country Link
US (2) US6923956B1 (pt)
EP (3) EP1224940B2 (pt)
JP (1) JP4293497B2 (pt)
KR (2) KR100711990B1 (pt)
AT (2) ATE224726T1 (pt)
AU (1) AU741300B2 (pt)
CA (1) CA2304808C (pt)
DE (2) DE59811910D1 (pt)
DK (1) DK1017413T4 (pt)
ES (2) ES2223017T5 (pt)
IL (3) IL135186A0 (pt)
PT (2) PT1224940E (pt)
WO (1) WO1999015193A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
CA2304808C (en) 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
CN1703233A (zh) * 2002-07-12 2005-11-30 米德列斯公司 防止蛋白氧化降解的方法和组合物
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
JP4845741B2 (ja) * 2003-12-23 2011-12-28 ファルマシア コーポレーション 安定な成長ホルモン液体製剤
NZ550926A (en) 2004-05-17 2010-01-29 Ares Trading Sa Hydrogel interferon formulations
CN1993139B (zh) * 2004-06-01 2011-02-16 阿雷斯贸易股份有限公司 稳定的干扰素液体制剂
UA93349C2 (ru) * 2004-06-01 2011-02-10 Эйрэс Трейдинг C.A. Способ стабилизации мономерного белка интерферона
KR101191536B1 (ko) * 2004-06-01 2012-10-15 아레스 트레이딩 에스.에이. 안정화된 인터페론 액상 제제
PL1809662T3 (pl) * 2004-11-10 2009-07-31 Novartis Vaccines & Diagnostics Inc Dezamidowany interferon-beta
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
ES2664924T3 (es) * 2005-08-26 2018-04-24 Ares Trading S.A. Procedimiento para la preparación del interferón beta glicosilado
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
DE102007050165B4 (de) * 2007-10-19 2010-06-17 Stiftung Tierärztliche Hochschule Hannover Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung
EP2234645B1 (en) * 2007-12-20 2012-05-02 Merck Serono S.A. Peg-interferon-beta formulations
US9119866B2 (en) * 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
DE102008060960A1 (de) * 2008-12-06 2010-06-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Optische Füllstandsmessung
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US8506797B2 (en) * 2011-04-10 2013-08-13 Therapeutic Proteins International, LLC Downstream bioprocessing device
US8852435B2 (en) * 2011-11-29 2014-10-07 Therapeutics Proteins International, LLC Purification and separation treatment assembly (PASTA) for biological products
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR102132050B1 (ko) * 2012-10-26 2020-07-10 루핀 아틀란티스 홀딩스 에스에이 티엔에프알에프씨 융합 단백질의 안정한 약학 조성물
EP2919812A4 (en) * 2012-11-19 2016-05-18 Merck Sharp & Dohme Liquid formulations for TNFR: FC fusion proteins
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
JP2687995B2 (ja) 1980-04-03 1997-12-08 バイオゲン インコーポレイテッド Ｄｎａ配列、組替えｄｎａ分子およびヒト繊維芽細胞インターフェロン様ポリペプチドの製造方法
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
DE3262575D1 (en) † 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
AU1234383A (en) 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
JPS59181224A (ja) † 1983-03-29 1984-10-15 Sumitomo Chem Co Ltd 安定なインタ−フエロン製剤の製法
US4816440A (en) 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
EP0284249A1 (en) † 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3712564A1 (de) 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
US4895716A (en) † 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
DE68917883T2 (de) * 1988-05-06 1995-02-23 Toray Industries Stabile interferon-beta-zusammensetzung.
US5272135A (en) † 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
DE4128319A1 (de) 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
JPH06247870A (ja) 1993-02-23 1994-09-06 Ajinomoto Co Inc インターロイキン−６を含有する医薬製剤
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
HU224222B1 (hu) 1996-12-24 2005-06-28 Biogen Inc. Stabil folyékony interferon-készítményformák és eljárás interferon stabilizálására
CA2304808C (en) † 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations

Also Published As

Publication number Publication date
AU741300B2 (en) 2001-11-29
KR100826621B1 (ko) 2008-05-02
EP1224940B1 (de) 2004-09-01
CA2304808C (en) 2011-03-22
EP1224940B2 (de) 2010-08-11
US8337826B2 (en) 2012-12-25
JP2001517635A (ja) 2001-10-09
ES2223017T5 (es) 2010-10-15
ES2223017T3 (es) 2005-02-16
IL211048A (en) 2012-12-31
EP1017413B2 (de) 2007-11-07
IL135186A (en) 2012-12-31
ES2181281T3 (es) 2003-02-16
KR20060088910A (ko) 2006-08-07
DK1017413T4 (da) 2008-03-25
DE59811910D1 (de) 2004-10-07
US20050186177A1 (en) 2005-08-25
JP4293497B2 (ja) 2009-07-08
AU9627698A (en) 1999-04-12
EP1224940A1 (de) 2002-07-24
ATE224726T1 (de) 2002-10-15
PT1224940E (pt) 2005-01-31
WO1999015193A1 (de) 1999-04-01
EP1426058A2 (de) 2004-06-09
DK1017413T3 (da) 2003-02-03
US6923956B1 (en) 2005-08-02
KR20010015599A (ko) 2001-02-26
EP1224940A8 (de) 2002-11-20
IL135186A0 (en) 2001-05-20
ES2181281T5 (es) 2008-04-16
DE59805732D1 (de) 2002-10-31
CA2304808A1 (en) 1999-04-01
KR100711990B1 (ko) 2007-05-02
EP1017413A1 (de) 2000-07-12
EP1426058A3 (de) 2004-07-28
ATE274917T1 (de) 2004-09-15
EP1017413B1 (de) 2002-09-25

Similar Documents

Publication Publication Date Title
PT1017413E (pt) Formulacoes liquidas de interferao (beta)
LV10178A (lv) Fiziologiski saderigu glabajot stabilu cilveka olbaltumvielu preparatu iegusanas panemiens
ES8603271A1 (es) Un metodo de producir una composicion de interleuquina-2
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
PL319833A1 (en) Compounds and composition for carrying active media
ATE106247T1 (de) Formulierung für rekombinantes beta-interferon, verfahren zur gewinnung und stabilisierung des beta-interferons und dessen verwendung.
DE69428040D1 (de) Orale darreichungsform
LU90806I2 (fr) Ovidrelle-choriogonadotropine alfa et ses d-riv-s pharmaceutiquement acceptables
DK0454898T3 (da) Glycosaminoglycan-modificeret protein, fremgangsmåde til fremstilling af proteinet, farmaceutiske præparater indeholdende proteinet samt anvendelse af proteinet
DE69630918D1 (de) Matrix für Iontophorese
IL84985A (en) Sialic acid derivatives with an active carbonyl group useful for extending biological half-life of physiological agents and as couplers for affinity chromatography
DE69009748D1 (de) Fgf enthaltende stabilisierte zubereitungen.
ES8900018A1 (es) Procedimiento para la fabricacion de derivados aminoalcoholes peptidicos inhibidores de la renina y de las proteasas acidas
CA2072797A1 (en) Use of tri (n-butyl) phosphate at low ph in solutions of biologically active proteins for enhanced virucidal activity
NO20003888L (no) Anti-enzympreparater omfattende etylendiamindiravsyre
ES2191825T3 (es) Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia.
WO1996005286A3 (en) Cell death accelerator and cell death inhibitor
FR2630457B1 (fr) Utilisation de l'acide para-amino-salicylique pour la stabilisation de l'activite enzymatique de la peroxydase en solution, agent stabilisant et solution stabilisee en comportant application
IT8820978A0 (it) Composizione erbicida conselettivita' aumentata e processo per la preparazione di entrambi i componenti ingredienti attivi in un solo stadio.
IT1233426B (it) Composizioni farmaceutiche per uso orale ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo, e procedimento per prepararle
IL101426A0 (en) Amino-coupled sialic acid derivatives with an active carbonyl group useful for extending biological half-life of physiological agents and as couplers for affinity chromatography
NZ509773A (en) Casein formulations for the delivery of bioactive constituents